PanOptica secures $11m to advance clinical development novel topical anti-VEGF eye drop
PanOptica a private biopharmaceutical company focused on developing innovative ophthalmology therapies, announced that it has secured $11m in a series B financing.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.